Table of Contents
On September 14, 2026, the FDA held a public hearing to gather input on how psychedelic medicines should be used after approval. Speakers disagreed sharply on provider qualifications, geographic access, the role of psychotherapy, and whether the existing evidence base is solid enough to support broad commercial rollout.
- Access is the central tension. A July FDA guidance requiring an on-call physician reachable within 15 minutes of a non-physician monitor raised concerns that rural and frontier clinics could be shut out entirely.
- Workforce questions remain unresolved. Psychiatrists, nurses, and credentialing organizations all made competing claims about who is qualified to oversee psychedelic dosing sessions, with no consensus emerging.
- Therapy versus drug-only models are still contested. Some clinicians argued that removing structured psychotherapy from treatment to isolate drug effects could reduce effectiveness, citing early ketamine data showing better outcomes with therapy included.
- Serious safety and methodological concerns were raised. One speaker cited small phase 3 sample sizes relative to large target populations, known cardiac risks, reports of sexual misconduct by providers, and questions about research integrity as reasons for caution before broad commercialization.
- Model
- human
- Sample
- Public FDA advisory hearing; multiple speakers including clinicians, researchers, advocates, and safety advocates
- Design
- Regulatory public comment hearing, September 14, 2026
- Key outcome
- No regulatory decision issued; hearing captured a wide range of unresolved stakeholder positions on access, provider qualifications, therapy integration, and safety
- Main limitation
- A public hearing is not a clinical study; the perspectives reported are stakeholder opinions, not controlled evidence
What the Research Examined
This recap covers a public FDA hearing held on September 14, 2026, reported by Darren Incorvaia at Fierce Biotech. The hearing was convened as the agency moves toward what could be the first formal approval of a psychedelic medicine in the United States. It is not a clinical trial. It is a public input process, and its outcomes are stakeholder positions, not controlled data.
The hearing drew clinicians, credentialing organizations, patient advocates, safety nonprofit founders, and policy critics. The companies closest to approval, Compass Pathways and Definium Therapeutics, have pursued a dosing session monitor model rather than a full psychotherapy model, a deliberate design choice meant to isolate the pharmacological effect of the drug itself. Definium announced its third phase 3 trial success on the same day as the hearing; Compass is in a rolling new drug application submission following two pivotal wins in depression. Those developments are part of the evolving regulatory landscape for psychedelic medicines that the hearing was designed to inform.
A July FDA guidance document had already introduced a contested requirement: if the lead monitor of a dosing session is not a physician, an on-call physician must be reachable within 15 minutes. Speakers from rural and frontier regions warned this could make approval meaningless for many communities. Meanwhile, a critic of the broader field, Kevin Sabet of the Foundation for Drug Policy Solutions, raised concerns about small trial sample sizes, methodological problems in existing research, and the political circumstances surrounding recent FDA priority review vouchers issued to three psychedelic developers. A co-founder of the Coalition for Psychedelic Safety and Education spoke about the death of her 21-year-old daughter following psychedelic use, underscoring that adverse events and cardiac risks remain real and serious considerations.
What the Findings Show
- Definium phase 3 results.Definium Therapeutics reported its third phase 3 trial success in 12 weeks on the day of the hearing, for its LSD-based formula targeting mental health conditions. No specific effect-size numbers were included in the source.
- Compass NDA status.Compass Pathways is in a rolling new drug application submission to the FDA following two pivotal trial wins in depression. No specific trial statistics were quoted in the source.
- Physician access rule.A July FDA guidance requires that if the lead dosing monitor is not a physician, an on-call physician must be able to reach the patient within 15 minutes, a threshold speakers said would exclude otherwise qualified clinics in rural areas.
- Anxiety disorder scale.One speaker noted that anxiety disorders are estimated to affect roughly one in six adults in the U.S., raising questions about whether current phase 3 sample sizes are adequate to support claims for a population that large.
The hearing produced no regulatory decisions or binding guidance. It documented a field in active disagreement about fundamental questions, including who is qualified to deliver psychedelic care, whether therapy must be part of treatment, how to handle geographic access barriers, and whether the pace of development is outrunning the science. These are the questions the FDA will need to answer in any approval conditions or risk mitigation strategies it eventually puts in place.
What did the FDA’s 2026 psychedelic hearing decide about who can administer psilocybin therapy?
The hearing reached no decisions. It surfaced deep disagreement among psychiatrists, nurses, credentialing bodies, and safety advocates about provider qualifications, the role of psychotherapy, rural access, and whether methodological concerns in existing trials are serious enough to slow the path to approval.
What This Is, and What It Is Not
This is This is a regulatory public comment hearing, not a clinical study, meaning no hypothesis was tested, no control group was used, and no data were collected beyond stakeholder testimony.
This is not This hearing does not constitute evidence that any psychedelic medicine is safe or effective for any condition, and nothing reported here should be taken as a guide to personal medical decisions. Educational purposes only.
Our Take
Within the Church, we hold psilocybin as a sacrament and we also hold the people who will encounter it in clinical settings as sacred. What the September 14 hearing made plain is that the institutional structures being designed around this medicine will shape who can access it, who guides them through it, and what kind of relationship exists between the person and the provider. The debate over DSMs versus therapists is not merely a regulatory technicality. It is a question about whether the inner life of the person going through the experience is considered part of the treatment at all. The safety concerns raised, including cardiac risks and the deaths already associated with unregulated use, remind us that reverence for the medicine includes taking its power seriously, not only in ceremony but in clinical design. A framework built on expediency rather than care would be a failure of both science and spirit.
If you are following the path toward working with psilocybin in any context, the questions being asked at the regulatory level are not distant from your own journey. How a medicine is held, who holds it, and what relationship surrounds the experience are the same questions at the heart of Integration. We welcome you to sit with these developments not as headlines but as part of a living conversation about what it means to receive something powerful with care and intention. The Mycelium Report exists to help you stay grounded in the science while keeping the deeper questions close.
Frequently Asked Questions
Has the FDA approved any psilocybin therapy yet?
As of the September 2026 hearing, no psychedelic medicine had received FDA approval. Compass Pathways is in a rolling new drug application process and Definium Therapeutics reported phase 3 successes, but formal approval had not been granted at the time of reporting.
What is a dosing session monitor in psychedelic clinical trials?
A dosing session monitor is a healthcare provider who supervises a patient during a psychedelic drug session. Companies like Compass and Definium use this model instead of a licensed therapist, partly to isolate the drug’s pharmacological effect from the influence of structured psychotherapy.
Why is the FDA’s 15-minute physician rule controversial?
A July 2026 FDA guidance requires an on-call physician to be reachable within 15 minutes if the lead monitor is not a physician. Speakers from rural and frontier states said this standard would make FDA-approved psychedelic therapy inaccessible in many communities regardless of clinic qualifications.
Are there safety risks associated with psychedelic medicines?
Yes. The hearing specifically highlighted cardiac risks, adverse events, and reports of sexual misconduct by providers as known concerns. One speaker described the death of her daughter following psychedelic use. Pre-screening and qualified supervision were cited as critical safeguards.
Does psychotherapy improve outcomes in psychedelic treatment?
Some early evidence suggests it may. One clinician cited ketamine trials comparing therapy-assisted and non-therapy-assisted conditions, which reportedly showed better outcomes when therapy was included. This evidence base is still limited and the field has not reached consensus.
Get the Mycelium Report
We read the new psilocybin and mushroom research so you do not have to. One honest, jargon-free dispatch, delivered daily. Free to join.
May love guide the hearts of all beings.
